Tseng-hui Timothy Chen

Title: Innovations of Tseng-hui Timothy Chen

Introduction

Tseng-hui Timothy Chen is a prominent inventor based in Burlingame, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of seven patents to his name, Chen's work focuses on innovative solutions for treating cancer and chronic viral infections.

Latest Patents

One of Chen's latest patents involves antibodies that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains). This invention provides not only the antibodies but also their antigen binding fragments, which have therapeutic applications. The methods of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. Additionally, the invention encompasses polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising these polynucleotides, and methods for producing the antibodies or fragments by expressing them from cells.

Career Highlights

Throughout his career, Tseng-hui Timothy Chen has worked with notable companies such as Bristol-Myers Squibb Company and Medarex Inc. His experience in these organizations has contributed to his expertise in the field of immunotherapy and antibody development.

Collaborations

Chen has collaborated with several professionals in his field, including Mark F. Maurer and Brigitte Devaux. These collaborations have likely enhanced the scope and impact of his research and innovations.

Conclusion

Tseng-hui Timothy Chen's contributions to biotechnology through his innovative patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in therapeutic applications for serious health conditions.